# A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

> **NCT06616636** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Rezatapopt

## Key facts

- **NCT ID:** NCT06616636
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-30
- **Primary completion:** 2027-08-27
- **Final completion:** 2029-08-27
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06616636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06616636, "A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06616636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*